Professor Ian Frazer.
A VACCINE being developed by Professor Ian Frazer to prevent and treat the herpes simplex virus (HSV-2) has proven to be safe in a phase 1 clinical trial.
Professor Frazer said the results were “very encouraging”.
He is hoping to extend the trial into the next phase which will be human trials with people infected with herpes.
The US CDC ( Centre for Disease Control) estimates that 1 in 6 people in the US between the age of 14 and 49 have contracted the virus.